Home / Therapeutic Area / Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

Published: Aug 2017 | Published By: GBI Research

Description

This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, with symptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior.

Finally, Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking.

The size of these pipelines ranges from 11 products in Tourette syndrome to 191 in depression. Across all four of these indications, however, transporters and receptors of neurotransmitters such as dopamine and serotonin are the most common targets, closely reflecting the current treatment landscape of these diseases.

Scope

  • Which companies are the most active within the pipeline for genetic neuropsychiatric disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of genetic neuropsychiatric disorders?

Reasons To Buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Executive Summary
Table of Contents
List of Tables
List of Figures
Introduction
Neuropsychiatric Disorder Cluster Report Coverage
Attention Deficit Hyperactivity Disorder (ADHD) – Overview
Depression – Overview
Schizophrenia – Overview
Tourette Syndrome – Overview
Therapeutics Development
Attention Deficit Hyperactivity Disorder (ADHD)
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Depression
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Schizophrenia
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tourette Syndrome
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Therapeutics Assessment
Attention Deficit Hyperactivity Disorder (ADHD)
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Depression
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Schizophrenia
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tourette Syndrome
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Companies Involved in Therapeutics Development
Attention Deficit Hyperactivity Disorder (ADHD)
Aevi Genomic Medicine Inc
Alcobra Ltd
Amarantus Bioscience Holdings Inc
APeT Holding BV
Arbor Pharmaceuticals LLC
BCWorld Pharm Co Ltd
BioHealthonomics Inc
BioLite Inc
Cingulate Therapeutics LLC
Collegium Pharmaceutical Inc
Curemark LLC
DURECT Corp
Eli Lilly and Company
Ensysce Biosciences Inc
H. Lundbeck A/S
Heptares Therapeutics Ltd
Highland Therapeutics Inc
Integrative Research Laboratories Sweden AB
INVENT Pharmaceuticals Inc
KemPharm Inc
Luc Therapeutics Inc
Merck & Co Inc
Neos Therapeutics Inc
NeuroDerm Ltd
Neurovance Inc
NLS Pharma Group
Noven Pharmaceuticals Inc
P2D Bioscience
Reviva Pharmaceuticals Inc
Shire Plc
SK Biopharmaceuticals Co Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Taisho Pharmaceutical Co Ltd
TRImaran Pharma Inc
Depression
4D Pharma PLC
AB Science SA
Acadia Pharmaceuticals Inc
Adamed Sp z oo
Addex Therapeutics Ltd
Aequus Pharmaceuticals Inc
Alkermes Plc
Allergan Plc
Alvogen Korea Co Ltd
Amorsa Therapeutics Inc
Anavex Life Sciences Corp
Angelini Group
Angita BV
Araim Pharmaceuticals Inc
AstraZeneca Plc
Avanir Pharmaceuticals Inc
Axsome Therapeutics Inc
Azevan Pharmaceuticals Inc
BioCrea GmbH
BioLite Inc
Bionomics Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Calico LLC
Celgene Corp
Celon Pharma SA
Cerecor Inc
Clera Inc
Delpor Inc
Domain Therapeutics SA
Eisai Co Ltd
Eli Lilly and Company
Evotec AG
F. Hoffmann-La Roche Ltd
Fabre-Kramer Pharmaceuticals Inc
FPRT Bio Inc
GlaxoSmithKline Plc
GliaCure Inc
H. Lundbeck A/S
Heptares Therapeutics Ltd
Hua Medicine (Shanghai) Ltd
Hyundai Pharmaceutical Co Ltd
Impel NeuroPharma Inc
INSYS Therapeutics Inc
Intas Pharmaceuticals Ltd
Intra-Cellular Therapies Inc
INVENT Pharmaceuticals Inc
Johnson & Johnson
KemPharm Inc
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings Inc
Luye Pharma Group Ltd
Mapi Pharma Ltd
Mapreg SAS
Medlab Clinical Ltd
Meta-IQ ApS
Methylation Sciences Inc
miCure Therapeutics Ltd
Mitsubishi Tanabe Pharma Corp
Navya Biologicals Pvt Ltd
Neuralstem Inc
Neurocrine Biosciences Inc
NeuroNascent Inc
NeurOp Inc
Newron Pharmaceuticals SpA
Nippon Chemiphar Co Ltd
nLife Therapeutics SL
Omeros Corp
Orexigen Therapeutics Inc
Otsuka Holdings Co Ltd
Pfizer Inc
Pherin Pharmaceuticals Inc
Polleo Pharma Ltd
Protagenic Therapeutics Inc
Relmada Therapeutics Inc
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
Sage Therapeutics Inc
Saniona AB
SK Biopharmaceuticals Co Ltd
Sound Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Supernus Pharmaceuticals Inc
Suven Life Sciences Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Company Ltd
Tetra Discovery Partners LLC
Trevena Inc
TRImaran Pharma Inc
VistaGen Therapeutics Inc
Zhejiang Huahai Pharmaceutical Co Ltd
Zogenix Inc
Zysis Ltd
Schizophrenia
Acadia Pharmaceuticals Inc
Adamed Sp z oo
Aequus Pharmaceuticals Inc
AgeneBio Inc
Alkermes Plc
Angita BV
Astellas Pharma Inc
Athersys Inc
Avanir Pharmaceuticals Inc
Avineuro Pharmaceuticals Inc
BCWorld Pharm Co Ltd
BioCrea GmbH
BioHealthonomics Inc
Boehringer Ingelheim GmbH
Braeburn Pharmaceuticals Inc
Bristol-Myers Squibb Company
Critical Pharmaceuticals Ltd
Curemark LLC
Daewoong Pharmaceutical Co Ltd
Delpor Inc
Denovo Biopharma LLC
Evotec AG
F. Hoffmann-La Roche Ltd
Fabre-Kramer Pharmaceuticals Inc
Galenea Corp
GeNeuro SA
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
GP Pharm SA
GW Pharmaceuticals Plc
H. Lundbeck A/S
Heptares Therapeutics Ltd
Hisamitsu Pharmaceutical Co Inc
Indivior Plc
Insys Therapeutics Inc
IntelGenx Corp
Intra-Cellular Therapies Inc
Johnson & Johnson
JT Pharmaceuticals Inc
Karuna Pharmaceuticals Inc
KemPharm Inc
Kowa Company Ltd
Laboratorios Farmaceuticos Rovi SA
Lead Discovery Center GmbH
Lohocla Research Corp
Luye Pharma Group Ltd
Mapi Pharma Ltd
Merck & Co Inc
Mitsubishi Tanabe Pharma Corp
Neurocrine Biosciences Inc
NeurOp Inc
Newron Pharmaceuticals SpA
Omeros Corp
Otsuka Holdings Co Ltd
Peptron Inc
Pfizer Inc
Promentis Pharmaceuticals Inc
Ra Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
Sage Therapeutics Inc
SK Biopharmaceuticals Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Sunovion Pharmaceuticals Inc
Suven Life Sciences Ltd
Taisho Pharmaceutical Holdings Co Ltd
Tetra Discovery Partners LLC
Teva Pharmaceutical Industries Ltd
Vanda Pharmaceuticals Inc
Vitality Biopharma Inc
VLP Therapeutics LLC
Zogenix Inc
Zysis Ltd
Tourette Syndrome
Abide Therapeutics Inc
Catalyst Pharmaceuticals Inc
Neurocrine Biosciences Inc
Psyadon Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Synchroneuron Inc
Teva Pharmaceutical Industries Ltd
Therapix Biosciences Ltd
Dormant Projects
Attention Deficit Hyperactivity Disorder (ADHD)
Depression
Schizophrenia
Tourette Syndrome
Discontinued Products
Attention Deficit Hyperactivity Disorder (ADHD)
Depression
Schizophrenia
Tourette Syndrome
Product Development Milestones
Attention Deficit Hyperactivity Disorder (ADHD)
Featured News & Press Releases
Depression
Featured News & Press Releases
Schizophrenia
Featured News & Press Releases
Tourette Syndrome
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +